Semaglutide
Metabolic & Weight ManagementGLP-1 receptor agonist for weight loss and metabolic health, marketed as Ozempic and Wegovy.
Key Benefits
- ✓Significant weight loss (15-20%)
- ✓Improved insulin sensitivity
- ✓Reduced appetite and cravings
- ✓Better blood sugar control
- ✓Cardiovascular benefits
- ✓Reduced inflammation
Dosing Information
Detailed Protocol
Administered via subcutaneous injection once weekly. Start with lowest dose and gradually titrate up over 16-20 weeks to minimize GI side effects. Best injected in abdomen, thigh, or upper arm.
About Semaglutide
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that mimics the action of the natural GLP-1 hormone. It slows gastric emptying, reduces appetite, improves insulin secretion, and promotes significant weight loss. FDA-approved for both type 2 diabetes and chronic weight management.
Research Notes
Multiple large clinical trials (STEP 1-5, SELECT) have demonstrated Semaglutide efficacy for weight loss and cardiovascular risk reduction. FDA-approved in 2021 for weight management at 2.4mg dose (Wegovy).
Potential Side Effects
- •Nausea (common initially)
- •Vomiting
- •Diarrhea
- •Constipation
- •Abdominal pain
- •Potential pancreatitis (rare)
- •Gallbladder issues
Always consult with a healthcare professional before starting any peptide therapy.